Literature DB >> 26442901

Rapamycin Increases Mortality in db/db Mice, a Mouse Model of Type 2 Diabetes.

Kavithalakshmi Sataranatarajan1, Yuji Ikeno2, Alex Bokov3, Denis Feliers1, Himabindu Yalamanchili1, Hak Joo Lee1, Meenalakshmi M Mariappan1, Hooman Tabatabai-Mir1, Vivian Diaz4, Sanjay Prasad1, Martin A Javors1, Goutam Ghosh Choudhury5, Gene B Hubbard6, Jeffrey L Barnes1, Arlan Richardson7, Balakuntalam S Kasinath8.   

Abstract

We examined the effect of rapamycin on the life span of a mouse model of type 2 diabetes, db/db mice. At 4 months of age, male and female C57BLKSJ-lepr (db/db) mice (db/db) were placed on either a control diet, lacking rapamycin or a diet containing rapamycin and maintained on these diets over their life span. Rapamycin was found to reduce the life span of the db/db mice. The median survival of male db/db mice fed the control and rapamycin diets was 349 and 302 days, respectively, and the median survival of female db/db mice fed the control and rapamycin diets was 487 and 411 days, respectively. Adjusting for gender differences, rapamycin increased the mortality risk 1.7-fold in both male and female db/db mice. End-of-life pathological data showed that suppurative inflammation was the main cause of death in the db/db mice, which is enhanced slightly by rapamycin treatment.
© The Author 2015. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Life span; Obesity; Toxicity; mTOR Inhibition

Mesh:

Substances:

Year:  2015        PMID: 26442901      PMCID: PMC4906320          DOI: 10.1093/gerona/glv170

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  51 in total

1.  Rapamycin extends maximal lifespan in cancer-prone mice.

Authors:  Vladimir N Anisimov; Mark A Zabezhinski; Irina G Popovich; Tatiana S Piskunova; Anna V Semenchenko; Margarita L Tyndyk; Maria N Yurova; Marina P Antoch; Mikhail V Blagosklonny
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

2.  Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis.

Authors:  Xiaojie Zhang; Liang Li; Sheng Chen; Dehua Yang; Yi Wang; Xin Zhang; Zheng Wang; Weidong Le
Journal:  Autophagy       Date:  2011-04-01       Impact factor: 16.016

3.  Housing density does not influence the longevity effect of calorie restriction.

Authors:  Yuji Ikeno; Gene B Hubbard; Shuko Lee; Arlan Richardson; Randy Strong; Vivian Diaz; James F Nelson
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2005-12       Impact factor: 6.053

4.  Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue.

Authors:  Vanessa P Houde; Sophie Brûlé; William T Festuccia; Pierre-Gilles Blanchard; Kerstin Bellmann; Yves Deshaies; André Marette
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

5.  Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.

Authors:  Teruaki Fujishita; Koji Aoki; Heidi A Lane; Masahiro Aoki; Makoto M Taketo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-03       Impact factor: 11.205

6.  Rapamycin extends life and health in C57BL/6 mice.

Authors:  Yiqiang Zhang; Alex Bokov; John Gelfond; Vanessa Soto; Yuji Ikeno; Gene Hubbard; Vivian Diaz; Lauren Sloane; Keith Maslin; Stephen Treaster; Samantha Réndon; Holly van Remmen; Walter Ward; Martin Javors; Arlan Richardson; Steven N Austad; Kathleen Fischer
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-05-16       Impact factor: 6.053

7.  Rapamycin extends murine lifespan but has limited effects on aging.

Authors:  Frauke Neff; Diana Flores-Dominguez; Devon P Ryan; Marion Horsch; Susanne Schröder; Thure Adler; Luciana Caminha Afonso; Juan Antonio Aguilar-Pimentel; Lore Becker; Lillian Garrett; Wolfgang Hans; Moritz M Hettich; Richard Holtmeier; Sabine M Hölter; Kristin Moreth; Cornelia Prehn; Oliver Puk; Ildikó Rácz; Birgit Rathkolb; Jan Rozman; Beatrix Naton; Rainer Ordemann; Jerzy Adamski; Johannes Beckers; Raffi Bekeredjian; Dirk H Busch; Gerhard Ehninger; Jochen Graw; Heinz Höfler; Martin Klingenspor; Thomas Klopstock; Markus Ollert; Jörg Stypmann; Eckhard Wolf; Wolfgang Wurst; Andreas Zimmer; Helmut Fuchs; Valérie Gailus-Durner; Martin Hrabe de Angelis; Dan Ehninger
Journal:  J Clin Invest       Date:  2013-07-25       Impact factor: 14.808

8.  Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival.

Authors:  Fresnida J Ramos; Steven C Chen; Michael G Garelick; Dao-Fu Dai; Chen-Yu Liao; Katherine H Schreiber; Vivian L MacKay; Elroy H An; Randy Strong; Warren C Ladiges; Peter S Rabinovitch; Matt Kaeberlein; Brian K Kennedy
Journal:  Sci Transl Med       Date:  2012-07-25       Impact factor: 17.956

9.  A mammalian protein targeted by G1-arresting rapamycin-receptor complex.

Authors:  E J Brown; M W Albers; T B Shin; K Ichikawa; C T Keith; W S Lane; S L Schreiber
Journal:  Nature       Date:  1994-06-30       Impact factor: 49.962

10.  Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors.

Authors:  Carolina B Livi; Rulon L Hardman; Barbara A Christy; Sherry G Dodds; Diane Jones; Charnae Williams; Randy Strong; Alex Bokov; Martin A Javors; Yuji Ikeno; Gene Hubbard; Paul Hasty; Zelton Dave Sharp
Journal:  Aging (Albany NY)       Date:  2013-02       Impact factor: 5.682

View more
  23 in total

Review 1.  Mechanistic target of rapamycin signaling in mouse models of accelerated aging.

Authors:  Jin Young Lee; Brian K Kennedy; Chen-Yu Liao
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-01-01       Impact factor: 6.053

Review 2.  Disease drivers of aging.

Authors:  Richard J Hodes; Felipe Sierra; Steven N Austad; Elissa Epel; Gretchen N Neigh; Kristine M Erlandson; Marissa J Schafer; Nathan K LeBrasseur; Christopher Wiley; Judith Campisi; Mary E Sehl; Rosario Scalia; Satoru Eguchi; Balakuntalam S Kasinath; Jeffrey B Halter; Harvey Jay Cohen; Wendy Demark-Wahnefried; Tim A Ahles; Nir Barzilai; Arti Hurria; Peter W Hunt
Journal:  Ann N Y Acad Sci       Date:  2016-12       Impact factor: 5.691

3.  Cardioprotective effects of dietary rapamycin on adult female C57BLKS/J-Leprdb mice.

Authors:  Peter C Reifsnyder; Sergey Ryzhov; Kevin Flurkey; Rea P Anunciado-Koza; Ian Mills; David E Harrison; Robert A Koza
Journal:  Ann N Y Acad Sci       Date:  2018-01-29       Impact factor: 5.691

Review 4.  Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island.

Authors:  Sebastian I Arriola Apelo; Dudley W Lamming
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2016-05-21       Impact factor: 6.053

5.  Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice.

Authors:  Sebastian I Arriola Apelo; Cassidy P Pumper; Emma L Baar; Nicole E Cummings; Dudley W Lamming
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2016-04-18       Impact factor: 6.053

6.  Dysregulation of metabolic flexibility: The impact of mTOR on autophagy in neurodegenerative disease.

Authors:  Kenneth Maiese
Journal:  Int Rev Neurobiol       Date:  2020-08-11       Impact factor: 3.230

Review 7.  Energetic interventions for healthspan and resiliency with aging.

Authors:  Derek M Huffman; Marissa J Schafer; Nathan K LeBrasseur
Journal:  Exp Gerontol       Date:  2016-05-31       Impact factor: 4.032

Review 8.  Cognitive impairment with diabetes mellitus and metabolic disease: innovative insights with the mechanistic target of rapamycin and circadian clock gene pathways.

Authors:  Kenneth Maiese
Journal:  Expert Rev Clin Pharmacol       Date:  2020-01-03       Impact factor: 5.045

9.  Hydrogen sulfide ameliorates aging-associated changes in the kidney.

Authors:  Hak Joo Lee; Denis Feliers; Jeffrey L Barnes; Sae Oh; Goutam Ghosh Choudhury; Vivian Diaz; Veronica Galvan; Randy Strong; James Nelson; Adam Salmon; Christopher G Kevil; Balakuntalam S Kasinath
Journal:  Geroscience       Date:  2018-05-01       Impact factor: 7.713

Review 10.  Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2021       Impact factor: 1.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.